Bio-Plex

Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.

It is imperative to plan and prepare ahead of time for your research using Bio-Plex Assays to be successful. Good assay planning and preparation reduces mistakes and makes for a stress-free assay run. In this series of short videos, we share some simple steps you can take to make sure your work goes smoothly.

Develop new assays in just one day with the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit. See how in this webinar.

Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assays provide reliably measure neutralizing antibodies in less than 3 hours. Watch our webinar to learn more.

Circulation of SARS-CoV-2 in the global population led to the emergence of new variants threatening to undermine vaccine effectiveness. Understanding the immune response and its neutralizing abilities at both the patient level and globally could not only help prevent outbreaks but also mitigate the outcome for future pandemics.

With COVID-19 vaccines now widely available, case numbers in many areas are falling. But the question remains: How long does vaccine-induced immunity last? Measuring isotype-specific antibodies against SARS-CoV-2 and the effectiveness of neutralizing antibodies against variants can help us better understand the duration and breadth of the humoral response. These data are critical to aid public health researchers and inform development decisions for vaccines and therapeutics. Read about the new Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel.

The Bio-Plex Assay development process is designed to produce high performance multiplex assays. We prioritize sensitivity, broad dynamic range, reproducibility, and shorter incubation times to get you meaningful results faster. Watch this video to learn more about our SMARTS approach to assay development.

Meet our newest product supporting the fight against SARS-CoV-2: the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel. This qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens (nucleocapsid, receptor binding domain, spike 1, and spike 2).

Mice are critical model organisms for the study of neuroinflammation. But tissue quantity is often a limiting factor. In a recent paper, researchers describe a protocol for analysis of 33 cytokines and chemokines using only 50 μl of tissue homogenate. The remaining homogenate can be used for RNA extraction or other analysis.

In vaccine development, safety and efficacy are critical. Recent studies have shown that multiplex immunoassays offer a flexible way to monitor immune responses. With the ever-increasing pressure on scientists to develop a practical COVID-19 vaccine, multiplex immunoassays stand out as a proven tool.